ArticleDrug delivery2017
Magnetically triggered drug release from nanoparticles and its applications in anti-tumor treatment.
Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 39 citations in OpenAlex.
- Metal-Based Nanoparticles and Their Relevant Consequences on Cytotoxicity Cascade and Induced Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Review
- The Fine-Tuned Release of Antioxidant from Superparamagnetic Nanocarriers under the Combination of Stationary and Alternating Magnetic Fields.Antioxidants (Basel, Switzerland) · 2021Article
- Transferrin-modified liposomes triggered with ultrasound to treat HeLa cells.Scientific reports · 2021Article
- Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment.Frontiers in oncology · 2021Review
- Biomedical Applications of Reactive Oxygen Species Generation by Metal Nanoparticles.Materials (Basel, Switzerland) · 2020Review
- Current trends and challenges in cancer management and therapy using designer nanomaterials.Nano convergence · 2019Review
- Fabrication of 6-gingerol, doxorubicin and alginate hydroxyapatite into a bio-compatible formulation: enhanced anti-proliferative effect on breast and liver cancer cells.Chemistry Central journal · 2018Article
- Iron Oxide Colloidal Nanoclusters as Theranostic Vehicles and Their Interactions at the Cellular Level.Nanomaterials (Basel, Switzerland) · 2018Article
- Engineered nanomaterial applications in perinatal therapeutics.Pharmacological research · 2018Review
- PLMA-b-POEGMA Amphiphilic Block Copolymers as Nanocarriers for the Encapsulation of Magnetic Nanoparticles and Indomethacin.Polymers · 2017Article
- The Potential of Nanotechnology in Medically Assisted Reproduction.Frontiers in pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to describe the magnetic nanoparticle-drug conjugates for improved control of drug delivery and drug release. The widely used anticancer agent Doxorubicin (DOX) was successfully conjugated via amine groups to the carboxylic functional groups coating magnetic nanoparticles (fluidMAG-CMX). Following purification of the nanoparticles, the conjugation of DOX on fluidMAG-CMX was confirmed using FTIR spectroscopy and confocal microscopy. The observed drug loading capacity of DOX was 22.3%. Studies of magnetically triggered release were performed under an oscillating magnetic field (OMF). DOX exhibited a significant release percentage of 70% under an OMF, as compared with the release in enzyme. A magnetic field turn-on and turn-off experiment was also conducted to confirm the control of drug release using this triggered system. In vivo experiments indicated that the tumor-inhibitory rate of CMX-DOX NPs under a magnetic field was higher than the other control groups. According to the toxicity assessments, CMX-DOX NPs were not noticeably toxic to mice at our tested dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.